This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Onpattro
  • /
  • APOLLO: The Study of an Investigational Drug, Pati...
Clinical trial

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Read time: 1 mins
Last updated:1st Nov 2013
Identifier: NCT01960348

The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis.

Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 225 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Study Start Date: November 2013
Actual Primary Completion Date: August 2017
Actual Study Completion Date: August 2017

- Active Comparator:
patisiran (ALN-TTR02)
- Placebo Comparator: Sterile Normal Saline (0.9% NaCl)

Category Value
Date last updated at source 2017-09-15
Study type(s) Interventional
Expected enrolment 225
Study start date 2013-11-01
Estimated primary completion date 2017-08-01

View full details